GPR131 Agonists Modulate GLP-1 for Glucose Homeostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GPR131 agonists are not yet commercially available for the treatment or prevention of diabetes, metabolic syndrome, liver disease, inflammation, and other related conditions, highlighting a need for additional compounds that can effectively modulate GPR131 activity.
Innovation Solution
Development of specific chemical compounds, such as those described in Formulas (I), (II), and (III), which act as GPR131 agonists or modulators, potentially increasing serum levels of glucagon-like peptide-1 (GLP-1) to improve glucose homeostasis and metabolic parameters, and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GPR131 agonists are developed to improve glucose homeostasis and treat metabolic diseases, then therapeutic benefits are achieved, but commercial availability is limited due to lack of developed compounds
Solution Approach 1:
The patent segments the GPR131 agonist development into multiple chemical series and structures (Formulas I, II, III with various substituents), providing a portfolio of compounds rather than a single molecule. This segmentation allows different compounds to be evaluated for therapeutic effectiveness and manufacturing feasibility independently.
Solution Approach 2:
The patent systematically varies chemical parameters (substituents A, B, D, E, G, L and positions) to create diverse agonist structures. This parameter exploration identifies compounds with optimal balance between therapeutic effectiveness and manufacturability, resolving the contradiction between reliability and ease of manufacture.
2Reliability
If GPR131 agonists are used to increase GLP-1 levels and improve insulin sensitivity, then metabolic parameters are improved, but the mechanism complexity increases
Solution Approach 1:
The patent utilizes GLP-1 as an intermediary molecule that mediates the effect of GPR131 agonists on glucose homeostasis. By targeting the GPR131-GLP-1 axis, the patent simplifies the therapeutic mechanism while achieving multiple metabolic benefits (increased insulin sensitivity, improved glucose homeostasis) through a well-understood intermediary pathway.
3Reliability
If GPR131 agonists are developed with specific chemical structures, then agonist activity is enhanced, but the number of compounds required increases
Solution Approach 1:
The patent designs GPR131 agonists with universal pharmacophore features (core imidazole or pyrazole structure with specific substituent patterns) that can be achieved through systematic modification of a limited set of building blocks. This universality allows multiple compounds to be generated from a core framework, reducing the total number of distinct compounds needed while maintaining agonist activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enhance glucose homeostasis by increasing GLP-1 levels, improving insulin sensitivity, reducing inflammation, and providing therapeutic benefits for diabetes, metabolic syndrome, and liver disease, offering potential treatments for these conditions.
Implementation Method 1
GPR131 (also known as BG37, TGR5, M-BAR, GPCR19, MGC40597, GPBAR1, and RUP43) is a GPCR that is activated by bile acids (BAs) such as lithocholic acid (LCA) and taurolithocholic acid (TLC), and oleanolic acid. Since this receptor is coupled to signaling through the GαS protein, activation of GPR131 results in increases in cAMP.
Data Source
AI summary
Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described.